


CLAIMS

1. Compounds, characterized in that they correspond to the general formula (I) below:



(I)


5 in which:

-  $R_1$  represents:

- (i) a  $-CH_3$  radical,
- (ii) a radical  $-CH_2-O-R_5$ ,
- (iii) a radical  $-COR_6$ ,

10  $R_5$  and  $R_6$  having the meanings given below,

- Ar represents a radical chosen from the radicals of formulae (a)-(e) below:



$R_7$  having the meaning given below,

15 -  $R_2$  and  $R_3$ , which may be identical or different, independently represent a radical chosen from:

- (i) a hydrogen atom,
- (ii) a radical chosen from tert-butyl, 1-methylcyclohexyl and 1-adamantyl radicals,
- (iii) a radical  $-OR_8$ ,  $R_8$  having the meaning given

below,

- (iv) a polyether radical,  
it being understood that at least one of the radicals  $R_2$  or  $R_3$  represents a radical (ii),
- 5 -  $R_2$  and  $R_3$  taken together can form, with the adjacent aromatic ring, a 5- or 6-membered saturated ring optionally substituted with methyl groups and/or optionally interrupted with an oxygen or sulphur atom,
- $R_4$  represents a hydrogen atom, a halogen atom, a lower alkyl radical, a radical  $OR_9$ , a polyether radical or a radical  $COR_{10}$ ,
- 10

$R_9$  and  $R_{10}$  having the meanings given below,

- $R_5$  represents a hydrogen atom, a lower alkyl radical or a radical  $COR_{11}$ ,


15  $R_{11}$  having the meaning given below,

- $R_6$  represents a radical chosen from:

- (i) a hydrogen atom,  
(ii) a lower alkyl radical,  
(iii) a radical  $OR_{12}$ ,

20  $R_{12}$  having the meaning given below,

- (iv) a radical of formula




$R'$  and  $R''$  having the meanings given below,

- $R_7$  represents a hydrogen atom, a halogen atom, a lower alkyl radical, a nitro radical, a radical  $OR_{13}$ , a polyether radical or a radical of the following
- 25

09719219-032801

formula:



$\text{R}_{13}$ ,  $\text{R}_{14}$  and  $\text{R}_{15}$  having the meanings given below,

- 5 -  $\text{R}_8$  represents a hydrogen atom, a lower alkyl radical, an optionally substituted aryl radical, an optionally substituted aralkyl radical, a monohydroxyalkyl or polyhydroxyalkyl radical or a lower acyl radical,
- 10 -  $\text{R}_9$  represents a hydrogen atom, a lower alkyl radical, an optionally substituted aryl radical, an optionally substituted aralkyl radical, a monohydroxyalkyl or polyhydroxyalkyl radical, a lower acyl radical, a radical  $-(\text{CH}_2)_n-\text{COOR}_{16}$  or a radical  $-(\text{CH}_2)_n-\text{X}$ ,
- $n$ ,  $\text{R}_{16}$  and  $\text{X}$  having the meanings given below,
- 15 -  $\text{R}_{10}$  and  $\text{R}_{11}$ , which may be identical or different, represent a lower alkyl radical,
- $\text{R}_{12}$  represents a hydrogen atom, a lower alkyl radical, an optionally substituted aryl or aralkyl radical, a monohydroxyalkyl radical or a polyhydroxyalkyl radical,
- 20 -  $\text{R}'$  and  $\text{R}''$ , which may be identical or different, represent a hydrogen atom, a lower alkyl radical, an optionally substituted aryl radical or an amino acid residue,
- or alternatively  $\text{R}'$  and  $\text{R}''$  taken together can form,
- 25 with the nitrogen atom, a heterocycle,
- $\text{R}_{13}$  represents a hydrogen atom or a lower alkyl

09719219-032801

M

radical,

- R<sub>14</sub> and R<sub>15</sub>, which may be identical or different, represent a hydrogen atom or a lower alkyl radical,

- R<sub>16</sub> represents a hydrogen atom or a lower alkyl

5 radical,

- n represents an integer between 1 and 12 inclusive,

- X represents a halogen atom,

and the optical and geometrical isomers of the said compounds of formula (I), as well as the salts thereof.

10 2. Compounds according to Claim 1, characterized in that they are in the form of salts of an alkali metal or alkaline-earth metal, of zinc, of an organic amine or of an inorganic or organic acid.

3. Compounds according to either of  
15 Claims 1 and 2, characterized in that the lower alkyl radicals are chosen from methyl, ethyl, isopropyl, butyl and tert-butyl radicals.

4. Compounds according to one of the preceding claims, characterized in that the  
20 monohydroxyalkyl radicals correspond to radicals containing 2 or 3 carbon atoms, in particular a 2-hydroxyethyl, 2-hydroxypropyl or 3-hydroxypropyl radical, it being possible for the monohydroxyalkyl radical to be protected in the form of acetyl or tert-  
25 butyldimethylsilyl.

5. Compounds according to one of the preceding claims, characterized in that the polyhydroxyalkyl radicals are chosen from

00719219-032801

M

2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl and  
2,3,4,5-tetrahydroxypentyl radicals or a  
pentaerythritol residue, it being possible for the  
hydroxyl groups to be protected in the form of acetyls  
5 or tert-butyldimethylsilyls.

6. Compounds according to one of the  
preceding claims, characterized in that the aryl  
radicals correspond to a phenyl radical, optionally  
substituted with at least one halogen, one hydroxyl or  
10 one nitro function.

7. Compounds according to one of the  
preceding claims, characterized in that the aralkyl  
radicals are chosen from benzyl and phenethyl radicals  
optionally substituted with at least one halogen, one  
15 hydroxyl or one nitro function.

8. Compounds according to one of the  
preceding claims, characterized in that the lower acyl  
radicals are chosen from an acetyl radical or a  
propionyl radical.

9. Compounds according to any one of the  
preceding claims, characterized in that the polyether  
radicals are chosen from methoxymethyl ether,  
methoxyethoxymethyl ether and methylthiomethyl ether  
radicals.

10. Compounds according to any one of the  
preceding claims, characterized in that the amino acid  
residues are chosen from the group consisting of  
residues derived from lysine, glycine or from aspartic

09719219-032301

acid.

11. Compounds according to any one of the preceding claims, characterized in that the heterocyclic radicals are chosen from the group consisting of piperidino, morpholino, pyrrolidino and piperazino radicals, optionally substituted in position 4 with a C<sub>1</sub>-C<sub>6</sub> alkyl radical or with a mono- or polyhydroxyalkyl radical.

12. Compounds according to Claim 1, characterized in that they are taken, alone or as mixtures, from the group consisting of:

ethyl 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate,

4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid,

ethyl 6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate,

6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,

ethyl 6-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate,

6-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,

3-(4-tert-butylphenylselanyl)benzoic acid,

6-(4-tert-butylphenylselanyl)nicotinic acid,

4-(4-tert-butylphenylselanyl)benzoic acid,

4-(4,4-dimethylthiochroman-8-ylselanyl)benzoic acid,

3-(4,4-dimethylthiochroman-8-ylselanyl)benzoic acid,

09719219-032801

Al

- 6-(4,4-dimethylthiochroman-8-ylselanyl)nicotinic acid,  
 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-  
 2-naphthylselanyl)benzoic acid,  
 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-  
 5 2-naphthylselanyl)benzoic acid,  
 6-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-  
 2-naphthylselanyl)nicotinic acid,  
 4-[5-adamantan-1-yl-4-(2-methoxyethoxymethoxy)-  
 2-methylphenylselanyl]benzoic acid,  
 10 3-[5-adamantan-1-yl-4-(2-methoxyethoxymethoxy)-  
 2-methylphenylselanyl]benzoic acid,  
 6-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 3-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-  
 15 5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid,  
 4-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl)-3-methoxybenzoic  
 acid,  
 3-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-  
 20 5,6,7,8-tetrahydro-2-naphthylselanyl)-4-methoxybenzoic  
 acid,  
 6-(4-methoxymethoxy-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 6-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-  
 25 5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 2-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid,  
 4-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-

09719219.032801  
 1008220.61267260

A1

- 5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid,  
 3-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid,  
 6-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)-  
 5 nicotinic acid,  
 2-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)-  
 nicotinic acid,  
 4-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)-  
 benzoic acid,  
 10 3-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)-  
 benzoic acid,  
 6-[4-adamantan-1-yl-3-benzyloxyphenylselanyl]nicotinic  
 acid,  
 6-(3,5-di-tert-butyl-2-benzyloxyphenylselanyl)nicotinic  
 15 acid,  
 3-methoxy-4-(4-benzyloxy-5,6,7,8-tetrahydro-  
 5,5,8,8-tetramethyl-2-naphthylselanyl)benzoic acid,  
 4-(4-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-  
 2-naphthylselanyl)benzoic acid,  
 20 6-(4-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-  
 2-naphthylselanyl)nicotinic acid,  
 3-methoxy-4-(3-benzyloxy-5,6,7,8-tetrahydro-  
 5,5,8,8-tetramethyl-2-naphthylselanyl)benzoic acid,  
 6-(3-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-  
 25 2-naphthylselanyl)nicotinic acid,  
 4-(3-hexyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-  
 2-naphthylselanyl)-3-methoxybenzoic acid,  
 6-(3-hexyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-

09719219-032801

M



- 2-naphthylselanyl)nicotinic acid,  
 4-(5-adamantan-1-yl-4-benzylloxy-2-methylphenylselanyl)-  
 benzoic acid,  
 6-[3-(5-hydroxypentyloxy)-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid,  
 ethyl 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-  
 2-naphthylselanyl)benzoate,  
 ethyl 4-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate,  
 10 ethyl 4-(3-hydroxy-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate,  
 4-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-  
 2-naphthylselanyl)benzoic acid,  
 ethyl 6-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-  
 15 5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate,  
 ethyl 6-(3-hydroxy-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate,  
 6-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-  
 2-naphthylselanyl)nicotinic acid,  
 20 ethyl 6-[3-(3-ethoxycarbonylpropoxy)-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinate,  
 6-[3-(3-carboxypropoxy)-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid,  
 ethyl 4-[3-(3-ethoxycarbonylpropoxy)-5,5,8,8-tetramethyl-  
 25 5,6,7,8-tetrahydro-2-naphthylselanyl]benzoate,  
 4-[3-(3-carboxypropoxy)-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl]benzoic acid,  
 ethyl 4-[3-(7-methoxycarbonylheptyloxy)-5,5,8,8-tetra-

09719219-032801

A1

- methyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoate,  
 4-[3-(7-carboxyheptyloxy)-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl]benzoic acid,  
 ethyl 6-[3-(7-methoxycarbonyl)heptyloxy)-5,5,8,8-tetra-  
 5 methyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinate,  
 6-[3-(7-carboxyheptyloxy)-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid,  
 ethyl 6-[3-(2-acetoxyethoxy)-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinate,  
 10 6-[3-(2-hydroxyethoxy)-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid,  
 ethyl 4-[3-(2-acetoxyethoxy)-5,5,8,8-tetramethyl-  
 5,6,7,8-tetrahydro-2-naphthylselanyl]benzoate,  
 4-[3-(2-hydroxyethoxy)-5,5,8,8-tetramethyl-  
 15 5,6,7,8-tetrahydro-2-naphthylselanyl]benzoic acid,  
 6-(3-adamantan-1-yl-4-methoxyphenylselanyl)nicotinic  
 acid,  
 [6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-  
 2-naphthylselanyl)-3-pyridyl]methanol,  
 20 N-ethyl-6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-  
 2-naphthylselanyl)nicotinamide,  
 morpholin-4-yl-[6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra-  
 hydro-2-naphthylselanyl)-3-pyridyl]methanone,  
 N-(4-hydroxyphenyl)-6-(3,5,5,8,8-pentamethyl-  
 25 5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinamide,  
 6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-  
 2-naphthylselanyl)pyridine-3-carbaldehyde.

13. Compounds according to Claim 1,

05719219-032801

characterized in that they have at least one, and preferably all, of the following characteristics:

- $R_1$  represents a radical  $COR_6$
- Ar represents a radical of formula (a) or (b)
- $R_2$  or  $R_3$  represents an adamantyl radical or  $R_2$

and  $R_3$  taken together form, with the adjacent aromatic ring, a 5- or 6-membered saturated ring optionally substituted with methyl groups and/or optionally interrupted with an oxygen or sulphur atom.

10            14. Compounds according to any one of the preceding claims, for use as medicinal products.

15            15. Compounds according to Claim 14, for use as medicinal products intended for treating dermatological complaints associated with a keratinization disorder which has a bearing on differentiation and on proliferation, in particular for treating common acne, comedones, polymorphonuclear leukocytes, rosacea, nodulocystic acne, acne conglobata, senile acne, secondary acnes such as solar, medication-related or occupational acne; for treating other types of keratinization disorder, in particular ichthyosis, ichthyosiform states, Darier's disease, palmoplantar keratoderma, leucoplasias and leucoplasiform states, and cutaneous or mucous (buccal) lichen; for treating other dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component and, in particular, all forms of psoriasis, whether it is

09719219-000001

AI  
CMT

July 1992

cutaneous, mucous or unguinal psoriasis and even psoriatic rheumatism, or alternatively cutaneous atopy, such as eczema or respiratory atopy or alternatively gingival hypertrophy; the compounds can also be used in

5 certain inflammatory complaints which have no keratinization disorder; for treating all dermal or epidermal proliferations, whether benign or malignant and whether they are of viral origin or otherwise, such as common warts, flat warts and verruciform

10 epidermodysplasia, oral or florid papillomatoses and proliferations which may be induced by ultraviolet radiation, in particular in the case of basocellular and spinocellular epithelioma; for treating other

15 dermatological disorders such as bullosis and collagen diseases; for treating certain ophthalmological disorders, in particular corneopathies; for repairing or combating ageing of the skin, whether this is light-induced or chronological ageing, or for reducing actinic keratoses and pigmentations, or any pathologies

20 associated with chronological or actinic ageing; for preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy; for preventing or treating cicatrization

25 disorders or for preventing or repairing stretchmarks, or alternatively for promoting cicatrization; for combating disorders of sebaceous functioning such as the hyperseborrhoea of acne or simple seborrhoea; in

A2

00719219-032801

A2

the treatment or prevention of cancerous or precancerous states, more particularly promyelocyte leukaemias; in the treatment of inflammatory complaints such as arthritis; in the treatment of any general or skin complaint of viral origin; in the prevention or treatment of alopecia; in the treatment of dermatological complaints having an immunological component; in the treatment of complaints of the cardiovascular system such as arteriosclerosis, hypertension, non-insulin-dependent diabetes and obesity; in the treatment of skin disorders due to an exposure to U.V. radiation.

16. Pharmaceutical composition, characterized in that it comprises, in a pharmaceutically acceptable support, at least one of the compounds as defined in any one of Claims 1 to 13.

17. Composition according to Claim 16, characterized in that the concentration of compound(s) according to one of Claims 1 to 13 is between 0.001% and 5% by weight relative to the composition as a whole.

18. Cosmetic composition, characterized in that it comprises, in a cosmetically acceptable support, at least one of the compounds as defined in any one of Claims 1 to 13.

19. Composition according to Claim 18, characterized in that the concentration of compound(s) according to one of Claims 1 to 13 is between 0.001%

0974939-032804  
T08250-6T6T60

A2  
cont  
and 3% by weight relative to the composition as a whole.

20. Use of a cosmetic composition as defined in either of Claims 18 and 19, for body or hair hygiene.

09719249-032801  
FOBEE0-67261/60